Strategic Equity Capital plc · LSE:SEC
Strategic Equity Capital — Q2 2018 Earnings Presentation
40 slides from Strategic Equity Capital's earnings presentation, 2018
Slide 1: Strategic Equity Capital plc Q2 Update 2018
STRATEGIC EQUITY CAPITAL PLC Q2 Update 2018
Slide 2: Risk considerations
Risk considerations Risk Factors for Strategic Equity Capital plc (the Company”) – The general risk factors set out under the heading “D.1.Key Risks” of the Prospectus apply to the Company. In addition, potential investors should note the following factors: • There can be no guarantee that the inves
Slide 3: Notice to recipients
Notice to recipients This document is given to the recipient on condition that the recipient accepts that it is not a client of GVQ Investment Management Limited (“GVQIM”) and that hence, none of the client protections applicable to GVQIM’s clients are in fact in force or available, and GVQIM is not
Slide 4: 4
4
Slide 5: Contents
Contents Q2 Update 2018 • Executive Summary 7 • Performance 8 • Detailed portfolio analysis 16 Outlook 20 Conclusion 30 Appendix 32 5
Slide 6: Q2 Update 2018
Q2 UPDATE 2018
Slide 7: Executive summary
Executive summary • Difficult quarter; net assets per share increased by 0.2%. Strong performance across the majority of the portfolio was offset by weak share price performance from three holdings: IFG Group, Proactis and Equiniti • FTSE Small Cap ex IT index (the “index”¹) increased by 7.0%. Indiv
Slide 8: Fund performance
Fund performance SEC NAV performance against comparator index1 Annualised Total return % 25 20 16.1 15 12.3 12.6 12.3 9.6 10 7.0 6.4 6.5 5 1.9 0.2 0 3 months 1 year 7 Feb 2017* 3 years 5 years SEC NAV Total Return FTSE Small Cap x IT Total Return¹ Average 7.4% 8.3% 8.9% 10.6% 10.4% Net Cash Fund per
Slide 9: Q2 Attribution analysis
Q2 Attribution analysis Positive attribution (top five) bps GVQIM Comment In line AGM statement. Positive opinion received for Diclectin (for nausea and vomiting in pregnancy). Placing Alliance Pharma 173 and acquisition of rights to distribute Nizoral (anti-dandruff shampoo) in APAC towards the end
Slide 10: IFG Group - update
IFG Group - update News Flow GVQ View Sum of the Part Valuation • In February 2018, IFG Group announced • Whilst disappointed that the announced • In our view, the current group structure is they would consider a sale of one of their transaction fell through, we believe that the inefficient and mask
Slide 11: IFG Group – a reminder of the thesis
IFG Group – a reminder of the thesis IFG – a financial services company with two high quality discrete businesses • Structural growth from favourable long • Significant M&A in both the platform term trends including the need for and wealth management spaces. We individuals to manage their forsee ong
Slide 12: Proactis Holdings – update
Proactis Holdings – update News Flow Detail on Customer Losses Why do we remain positive? • In August 2017, Proactis acquired a US • Both customers, although large in financial • Despite the disappointing update, which we peer, Perfect Commerce, roughly doubling terms, were ‘non-core’ in many ways:
Slide 13: Proactis Holdings – a reminder of the thesis
Proactis Holdings – a reminder of the thesis Proactis – a global provider of e-procurement and spend control software as a service (SaaS) • High quality and complementary product • Large, but fragmented market with suite drives strong organic growth. benefits of scale; further consolidation Strong c
Slide 14: Equiniti – update
Equiniti – update News Flow Why are the shares weak? Why do we remain positive? • Completion of transformational acquisition • Despite what we view as continued strong • We place high importance on earnings quality and of Wells Fargo Shareholder Services operational and financial delivery by the cas
Slide 15: Equiniti – a reminder of the thesis
Equiniti – a reminder of the thesis Equiniti – a market leading specialist business process outsourcer • Customers include 70% of FTSE 100 • High value on the strength of cash companies and 80%¹ of newly listed flows and structural growth drivers to companies both PE and trade: • Opportunity to sell
Slide 16: Changes to top holdings
Changes to top 10 holdings Top 10 Q1 2018 Top 10 Q2 2018 Company % of portfolio Company % of portfolio IFG Group 9.7 Tribal Group 8.7 Equiniti Group 9.0 Wilmington 8.5 Tribal Group 8.6 Equiniti Group 8.2 Wilmington 8.4 IFG Group 7.7 Clinigen Group 7.0 Clinigen Group 7.2 4imprint Group 6.4 4imprint G
Slide 17: Top holdings
Top 10 holdings1 GVQIM GVQIM Net debt/ Progress Company Vintage Sector Funds % of CF yield3 EBITDA Investment thesis Market leader2 vs thesis company NTM4 NTM4 Delivery of operational improvements; Tribal Group 2014 Technology >5% In line 8.0% -1.4x new platform development; contract wins; Yes – UK/
Slide 18: Highly concentrated and unconstrained portfolio
Highly concentrated and unconstrained portfolio Sector exposure by value Value by market cap band 10 1 Technology – software & services 22.1% 8 1 2 1 <£50m 0.0% 8 9 7 1 3 Healthcare 18.5% 2 £50m - £100m 4.6% 7 6 3 Support Services 15.2% 3 3 £100m - £200m 28.3% 4 Financials 14.2% 6 4 £200m - £300m 12
Slide 19: Portfolio valuation
Portfolio valuation1 SEC SEC FTSE UK Small Cap ex weighted average median investment trusts Number of securities 18 18 157 Market cap (£m) 422 211 317 Consensus EV/EBITDA FY1 9.8x 9.5x 7.0x Consensus price earnings FY1 15.5x 14.9x 11.2x Consensus FY1 earnings growth 16.1% 15.0% 7.7% Consensus divide
Slide 20: Outlook
OUTLOOK
Slide 21: Earnings growth, cashflow and M&A to drive returns
Earnings growth, cashflow and M&A to drive returns SEC portfolio • Mid teens aggregate earnings growth • Private Equity ‘dry powder’ at record for the portfolio levels. Increasing number of transactions in the public market; • Portfolio growth exceeds the market, Servelec, Laird, Hogg Robinson, desp
Slide 22: Five-year valuation analysis P/E Ratio (NTM)
Five-year valuation analysis 50 45 40 35 P/E Ratio (NTM) 30 25 20 15 10 5 0 Tribal Wilmington Equiniti IFG Group Clinigen 4imprint EMIS Tyman Medica Harworth Proactis (P/BK x10) Grey bars denote the 5 year range of P/E (NTM) valuations. Blue diamonds denote the closing P/E (NTM) rating Although our
Slide 23: Portfolio investment themes
Portfolio investment themes DIVERSIFIED DIGITAL HEALTH REGULATION AND PENSIONS INFRASTRUCTURE PHARMA COMPLIANCE AND AND SAVINGS BUILDING Demographic and Digital maturity agenda; Increasing compliance Increase in complexity US single family population changes replacement of legacy and regulatory burd
Slide 24: Market outlook and portfolio position
Market outlook and portfolio position Debt/monetary Macro Valuations M&A tightening Market European target M&A in H118 Significant uncertainty Pockets of small cap are of $770bn - the highest since remains in the UK and global trading at peak multiples often Increasing inflationary 2007 geopolitical
Slide 25: Bear market checklist
Bear market checklist Start of Proper Bear Markets Mar-00 Oct-07 Now Global Equity Valuations Trailing PE 33 17 18 Fwd PE 24 14 15 DY 1.3 2.1 2.4 CAPE 48 30 24 Global Equity Risk Premium 1.0% 3.3% 3.4% US Yield Curve (10Y minus 2Y) -0.5 0.0 0.3 Sentiment Global Analyst Bullishness (std dev) 1.7 1.0
Slide 26: Global private equity dry powder levels at record highs
Global private equity dry powder levels at record highs Private Equity Dry Powder by Fund Type, 2008 - 2017 Worldwide M&A volumes in H1, 1998 - 2018 $2.5bn $2.0bn $1.5bn $1.0bn $0.5bn $0.0bn 1998 2003 2008 2013 2018 Over $10bn Between $5bn and $10bn Less than $5bn HY bond yields over time (Bloomberg
Slide 27: 12-month forward EPS growth projections
12-month forward EPS1 growth projections 12m forward EPS growth by FTSE index ex investment trusts May 2009 to date 50 40 30 20 10 0 -10 -20 -30 -40 -50 May 09 Nov 09 May 10 Nov 10 May 11 Nov 11 May 12 Nov 12 May 13 Nov 13 May 14 Nov 14 May 15 Nov 15 May 16 Nov 16 May 17 Nov 17 May 18 FTSE 100 Mid 2
Slide 28: MiFID II could exacerbate issues in small cap markets
MiFID II could exacerbate a number of well documented issues in small cap markets Impact of MiFID II on Small Caps Implications for SEC and Portfolio • Decreasing resources (and therefore effectiveness) on • For portfolio companies: Increasing importance of proper investor the ‘sell-side’ for small
Slide 29: Covering sell-side analysts by Market Capitalisation
Covering sell-side analysts by Market Capitalisation 600 30 24 500 25 22 400 18 20 300 15 12 200 10 7 100 5 2 0 0 £20m-£500m £500m-£1bn £1bn-£4bn £4bn-£10bn £10bn-£20bn £20bn+ Number of companies (LHS) Average number of analysts (RHS) There are a large number of smaller companies with limited sell-s
Slide 30: Conclusion
CONCLUSION
Slide 31: Conclusion
Conclusion • Difficult quarter with negative performance concentrated in a small number of holdings. These companies continue to be an area of focus and engagement. In each case, confidence remains in long term prospects supported by compelling valuations • Across the portfolio there are a significa
Slide 32: Appendix
APPENDIX
Slide 33: How we identify value in potential investments
How we identify value in potential investments Main focus of most Main focus of most PUBLIC EQUITY INVESTORS PRIVATE EQUITY INVESTORS All investments undergo All investments are valued in-house, prospective using an in house cash-flow and historic leveraged buy-out model modelling Focus on recent re
Slide 34: Asset quality
There are strict criteria for inclusion in our funds Speculative Fair valued GARP1 Under valued Recovery Turnaround Distress growth A A Investment Asset quality Asset quality focus B Avoid Avoid B C Avoid C GVQIM’s research process aims to identify high quality coveted assets with attractive cash fl
Slide 35: How we identify coveted assets
How we identify coveted assets We look for characteristics which GVQIM believes potential acquirers value highly Qualitative Quantitative • Niche market leaders • High and/or improving ROCE • Orderly end markets, with some growth • Strong cash conversion • Sustainable business model/franchise/unique
Slide 36: Our Black List screens out companies with fundamental business risks
Our Black List screens out companies with fundamental business risks Operational • Excessive reliance on a single product, customer, supplier or distributor • The primary driver of profitability cannot be influenced by management (e.g. resources) • Inherently low margins • Structurally declining mar
Slide 37: Research Committee ensures consistency of approach
Research Committee ensures consistency of approach Preliminary Investment Final Investment Monitoring Idea generation Investment Memorandum Recommendation & review Recommendation Materials • Watch list • Company description • Company meeting • Counterparty analysis • Progress against • M&A transacti
Slide 38: Long term track record
Long term track record Cumulative rebased total returns1 300 CAGR2 280 SEC NAV 20.8% 260 240 220 200 FTSE 250 ex IT 15.7% 180 FTSE Small Cap ex IT 14.8% 160 140 120 100 80 60 40 Jun 09 Jun 10 Jun 11 Jun 12 Jun 13 Jun 14 Jun 15 Jun 16 Jun 17 Jun 18 Strong cumulative performance since process improvem
Slide 39: Performance
Performance Calendar Year annual performance YTD 2017 2016 2015 2014 2013 2012 Share Price Total Return -7.9% 20.2% -9.0% 14.2% 32.7% 61.5% 25.6% NAV Total Return -4.8% 21.7% 6.3% 12.1% 18.1% 46.1% 21.3% FTSE Small Cap ex Investment Trusts Total Return 0.1% 15.6% 12.5% 13.0% -2.7% 43.9% 36.3% Establ
Slide 40: Contact details
Contact details For further information regarding the SEC please contact the GVQ Investment Management marketing team below, or visit the Company’s website: www.strategicequitycapital.com For general enquiries, please contact: GVQ Investment Management Limited 16 Berkeley Street, London, W1J 8DZ Tel
Strategic Equity Capital — Q2 2018 Earnings Presentation on 6ix